Abstract
Brain age has been widely investigated by using the whole brain image. However, the age of some specific brain regions, such as those related to the hippocampus, remains underexplored. This study developed age prediction models for left and right hippocampus-centred regions of interest (hippocampus ROI) using three-dimensional convolutional neural networks (3D-CNN) based on MRI scans from 31,370 healthy participants in the UK Biobank. The hippocampus ROI age (HA) gap was calculated by subtracting chronological age from predicted HA. Additionally, the longitudinal change rate of the HA gap was estimated in 3,893 participants with imaging data at two time points over an average follow-up of 2.63 years. The models achieved state-of-the-art performance (mean absolute error (MAE): 2.47 to 2.84 years). Cross-sectional analysis revealed that APOE ε4 homozygotes had a greater HA gap compared to APOE ε4 non-carriers. Participants with hypertension, diabetes, heavy alcohol consumption, or smoking also exhibited larger HA gap. Transfer learning applied to an independent dataset confirmed similar trends in some variables, though findings were not statistically significant. Interestingly, longitudinal analysis showed that APOE ε4 homozygotes had a higher annual change rate in the left HA gap compared to APOE ε2 homozygotes. Occlusion analysis saliency maps indicated that regions around the hippocampus, including the thalamus, pallidum, nearby cerebral cortex, and white matter, significantly contributed to the age prediction. The left HA gap emerges as a potential biomarker linked to the APOE genotype and an indicator of health.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Sydney Memory and Ageing Study has been funded by three National Health & Medical Research Council (NHMRC) Program Grants (ID350833, ID568969, and APP1093083).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
1. Written consent was acquired from all participants and ethics approval was provided by the National Health Service National Research Ethics Service. 2. Ethics approval was obtained from the Human Research Ethics Committees of the University of New South Wales and the South Eastern Sydney Local Health District.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
